131 related articles for article (PubMed ID: 18937233)
1. A third evaluation of tertiary cytoreduction.
Gultekin M; Velipaşaoğlu M; Aksan G; Dursun P; Dogan NU; Yuce K; Ayhan A
J Surg Oncol; 2008 Dec; 98(7):530-4. PubMed ID: 18937233
[TBL] [Abstract][Full Text] [Related]
2. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.
Karam AK; Santillan A; Bristow RE; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Li AJ
Gynecol Oncol; 2007 Feb; 104(2):377-80. PubMed ID: 17014899
[TBL] [Abstract][Full Text] [Related]
3. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
4. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience.
Ayhan A; Gultekin M; Taskiran C; Aksan G; Celik NY; Dursun P; Salman MC; Yuce K; Kucukali T
Am J Obstet Gynecol; 2006 Jan; 194(1):49-56. PubMed ID: 16389009
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
[TBL] [Abstract][Full Text] [Related]
6. [Secondary cytoreductions in the treatment of ovarian cancers].
Zylberberg B; Dormont D; Janklewicz S; Daraï E; Madelenat P; Antoine JM
Gynecol Obstet Fertil; 2000 Feb; 28(2):127-36. PubMed ID: 10758587
[TBL] [Abstract][Full Text] [Related]
7. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
Li YF; Li MD; Liu FY; Liu JH; Li JD
Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
[TBL] [Abstract][Full Text] [Related]
8. Recurrent micropapillary serous ovarian carcinoma.
Bristow RE; Gossett DR; Shook DR; Zahurak ML; Tomacruz RS; Armstrong DK; Montz FJ
Cancer; 2002 Aug; 95(4):791-800. PubMed ID: 12209723
[TBL] [Abstract][Full Text] [Related]
9. Tertiary cytoreduction in patients with recurrent ovarian carcinoma.
Leitao MM; Kardos S; Barakat RR; Chi DS
Gynecol Oncol; 2004 Oct; 95(1):181-8. PubMed ID: 15385129
[TBL] [Abstract][Full Text] [Related]
10. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
Zang RY; Yang WT; Shi DR; Xing Y; Cai SM
J Surg Oncol; 2005 Jul; 91(1):67-72. PubMed ID: 15999350
[TBL] [Abstract][Full Text] [Related]
11. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
12. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
[TBL] [Abstract][Full Text] [Related]
13. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
[TBL] [Abstract][Full Text] [Related]
14. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
Munkarah A; Levenback C; Wolf JK; Bodurka-Bevers D; Tortolero-Luna G; Morris RT; Gershenson DM
Gynecol Oncol; 2001 May; 81(2):237-41. PubMed ID: 11330956
[TBL] [Abstract][Full Text] [Related]
15. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
[TBL] [Abstract][Full Text] [Related]
16. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
17. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
[TBL] [Abstract][Full Text] [Related]
18. Primary cytoreductive surgery for epithelial ovarian cancer.
Hacker NF; Berek JS; Lagasse LD; Nieberg RK; Elashoff RM
Obstet Gynecol; 1983 Apr; 61(4):413-20. PubMed ID: 6828269
[TBL] [Abstract][Full Text] [Related]
19. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.
Munkarah AR; Coleman RL
Gynecol Oncol; 2004 Nov; 95(2):273-80. PubMed ID: 15491746
[TBL] [Abstract][Full Text] [Related]
20. Debulking surgery for incompletely operated advanced epithelial ovarian carcinoma.
Gultekin M; Dursun P; Doğan NU; Kolusari A; Yuce K; Ayhan A
J Surg Oncol; 2009 Sep; 100(3):258-60. PubMed ID: 19347889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]